文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

动态监测降钙素原与可溶性CD14亚型对严重脓毒症患者的评估价值

Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis.
PubMed 文献 · Am J Emerg Med · 2017-01-22
一句话结论严重脓毒症患者动态监测可溶性CD14亚型及其清除率,较降钙素原及其清除率更能持续反映疗效与预后。

该研究纳入109例严重脓毒症患者,按90天生存分为生存组与非生存组,在第1、3、5、7、12天检测降钙素原与可溶性CD14亚型水平并计算SOFA评分。降钙素原自第5天起与SOFA呈弱至中度正相关,可溶性CD14亚型自第3天起即呈正相关;可溶性CD14亚型清除率自第3天起与SOFA呈强负相关。降钙素原水平在生存组与非生存组间无统计学差异,两组降钙素原水平同步下降;可溶性CD14亚型在生存组持续下降而非生存组逐渐升高。作者认为可溶性CD14亚型及其清除率是优于降钙素原及其清除率的持续疗效与预后标志物。

要点

  • 可溶性CD14亚型自第3天起即与SOFA正相关,其清除率自第3天起与SOFA强负相关,早于降钙素原(第5天起)。
  • 降钙素原水平在生存组与非生存组间无统计学差异,两组降钙素原水平同步下降,难以区分预后。
  • 可溶性CD14亚型在生存组持续下降,非生存组逐渐升高;其清除率生存组持续升高,非生存组逐渐下降。
  • 降钙素原清除率在生存组第3、5、7、12天高于非生存组,但两组降钙素原清除率同步上升。
  • 作者认为可溶性CD14亚型及其清除率是评估严重脓毒症疗效与预后的更优持续标志物。

适用人群与场景

  • 严重脓毒症患者(n=109),按90天生存分为生存组与非生存组。

研究设计与关键结果

  • 研究纳入109例严重脓毒症患者,按90天生存分为生存组与非生存组,在第1、3、5、7、12天检测降钙素原与可溶性CD14亚型水平并计算SOFA评分。
  • 降钙素原自第5天起与SOFA呈弱至中度正相关,可溶性CD14亚型自第3天起即呈正相关。
  • 可溶性CD14亚型清除率自第3天起与SOFA呈强负相关,降钙素原清除率自第5天起与SOFA呈弱至中度负相关。
  • 降钙素原水平在生存组与非生存组间无统计学差异,12天内两组降钙素原水平同步下降。
  • 可溶性CD14亚型在生存组持续下降,非生存组逐渐升高;其清除率生存组持续升高,非生存组逐渐下降。
  • 降钙素原清除率在生存组第3、5、7、12天高于非生存组,但两组降钙素原清除率同步上升。

证据类型、等级与局限

  • 证据类型:研究论文(临床观察性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,动态监测可溶性CD14亚型及其清除率较降钙素原及其清除率更能持续评估严重脓毒症患者的疗效与预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: This study comparatively evaluated the value of dynamic procalcitonin (PCT) and presepsin measurements in assessing therapeutic efficacy and prognosis for patients with severe sepsis.

METHODS: Patients with severe sepsis (n=109) were enrolled and divided into survival and non-survival groups based on 90-day survival. PCT and presepsin levels were evaluated on days 1, 3, 5, 7, and 12. Sequential organ failure assessment (SOFA) was calculated.

RESULTS: PCT from day 5 onward was weakly to moderately positively correlated with SOFA, whereas presepsin from day 3 onward was positively correlated. From day 5 onward, the clearance ratio (CR) of PCT was weakly to moderately negatively correlated with SOFA, while the CR of presepsin was strongly negatively correlated as early as day 3. PCT levels had no statistical difference between survival and non-survival groups. Within 12days, PCT levels in both survival and non-survival groups decreased synchronously. Comparatively, presepsin levels in the survival group decreased persistently, while they rose gradually in the non-survival group. CRs of PCT in the survival group were higher than those in the non-survival group on days 3, 5, 7, and 12. However, CRs of PCT rose synchronously in both groups. Comparatively, CRs of presepsin in the survival group rose persistently, while they decreased gradually in the non-survival group.

CONCLUSIONS: Dynamic monitoring of presepsin and PCT demonstrated that both presepsin and CR of presepsin are continuous and better markers than are PCT and CR of PCT for evaluating the therapeutic efficacy and prognosis of patients with severe sepsis.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Yu H, Qi Z, Hang C, et al. Evaluating the value of dynamic procalcitonin and presepsin measurements for patients with severe sepsis. Am J Emerg Med. 2017. PMID: 28153679. doi:10.1016/j.ajem.2017.01.037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。